Experimental CAR-T therapy shows promise in small leukemia trial
NCT ID NCT05350787
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new CAR-T cell therapy called ThisCART19A in 10 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The main goals were to check safety and find the right dose. Researchers tracked side effects and how well the treatment shrank cancer cells in the first three months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ThisCART19A (a type of CAR-T cell therapy)
What this could lead to
If successful, this could point toward a new treatment option for patients with hard-to-treat B-cell leukemia who have few alternatives.
What could go wrong
This is a very early Phase 1 trial with only 10 participants, so results may not apply broadly. CAR-T therapies carry risks of severe side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Zhejiang Medical Colleage Zhejiang University
Hangzhou, Zhejiang, 310003, China
-
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, China